inVentiv Health opens phase I services in Miami
The services provided at this facility will complement the phase I through phase IV clinical capabilities offered at the company's existing bioanalytical labs and will draw on the company's deep commercial insights to design trials for success in today's value-driven environment.
"The Miami clinic is purpose-built to optimize trials for clients from the start," said Michael McKelvey, Ph.D., president, inVentiv Health Clinical Division and executive vice president, inVentiv Health. "Everything—from the location, to the pioneering processes we will use to enroll patients, to the ability to inject market access knowledge into the design strategy from the earliest phases of development—is intended to help clients improve trial execution, speed time to market and reduce development costs."
Clients will benefit from inVentiv Health's patient-centric approach to clinical trial enrollment, including the use of Mytrus Enroll eConsent technology, an efficient way of managing the informed consent process that allows trial volunteers to make better-informed decisions. Other services offered from the company's continuum of clinical services include novel and targeted patient identification, recruitment and engagement capabilities and strategic partnering and asset value optimization insights.
Riaz Bandali, president of early stage for inVentiv Health, said the vibrant, urban Life Science and Technology Park is an optimal location for the new phase I clinic. "Miami offers a large and diverse patient population, targeting a demographic our clients need and is a gateway to Latin America. The collaboration among Florida's business, education and life sciences industries will enable unique opportunities to design better solutions for our clients."
The Miami clinic will facilitate patient, special populations and normal healthy volunteer access to research for clients focused on complex studies, including first-in-human phase I, phase I-in-patient and other multifaceted phase I trials such as drug-drug interaction, biosimilar, first-to-file and 505b2 trials.